Search Results
Your search for ,WHo matches 21072 pages
Showing 3401 - 3450Personalized mRNA-Based Cancer Vaccine Plus Pembrolizumab for High-Risk Melanoma
mRNA-4157/V940, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma, and clinical benefit was observed regardless of tumor mutational...
First-Line Pembrolizumab Plus Gemcitabine/Cisplatin May Improve Overall Survival in Advanced Biliary Tract Cancer
The addition of pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented by Robin Katie Kelley, MD, and colleagues at the...
Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC: AEGEAN Trial
Treatment-naive patients with resectable non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response compared with those who received neoadjuvant chemotherapy alone,...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
NCCN 2023 Annual Conference: Quality-of-Life Issues
The National Comprehensive Cancer Network (NCCN) held its annual meeting recently in Orlando. On this week’s episode of <em>The ASCO Post Podcast</em>, we’ll hear from two presenters who discussed quality of life issues in individuals with cancer.
Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors
In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase inhibitor cabozantinib showed promising activity in patients with advanced clear cell renal cell...
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Cancer Susceptibility Germline Pathogenic Variants Among Older Patients
Hereditary cancer syndromes are caused by a pathogenic variant in cancer susceptibility genes, which overall account for approximately 10% of all cancers. Carriers of pathogenic variants are at an increased risk of developing cancer during their lifetime. Genomic cancer risk assessment makes it...
Addition of Ipilimumab to Nivolumab in Recurrent or Metastatic Head and Neck Cancer
As reported in JAMA Oncology by Kevin J. Harrington, MBBS, PhD, and colleagues, the phase II CheckMate 714 trial has shown that the addition of ipilimumab to nivolumab did not improve objective response rate as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of ...
Consensus Molecular Subtypes as Markers for Maintenance Therapy Regimens for RAS Wild-Type Metastatic Colorectal Cancer
In an analysis of the German phase II PanaMa trial reported in the Journal of Clinical Oncology, Stahler et al evaluated consensus molecular subtypes as prognostic and predictive biomarkers in patients with RAS wild-type metastatic colorectal cancer receiving fluorouracil and leucovorin with or...
GD2-CAR T Cells for Relapsed or Refractory High-Risk Neuroblastoma
In a single-institution Italian phase I/II trial reported in The New England Journal of Medicine, Del Bufalo et al found that treatment with chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2 expressed on tumor cells (GD2-CART01) produced responses in pediatric patients...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Mortality After Colonoscopy-Detected vs Postcolonoscopy-Diagnosed Colorectal Cancer in the VA Health-Care System
In a study reported in JAMA Network Open, Kahi et al found no differences in all-cause or cancer-specific mortality among veterans in the Veterans Affairs (VA) health-care system with colonoscopy-detected colorectal cancer vs those with postcolonoscopy-diagnosed colorectal cancer. Study Details...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Highlights From the NCCN 2023 Annual Conference
The National Comprehensive Cancer Network (NCCN) held its annual meeting recently in Orlando. On this week’s episode, we’ll hear from two of the presenters who discussed updates to the NCCN Clinical Practice Guidelines in Oncology in chronic lymphocytic leukemia/small lymphocytic lymphoma and CNS...
Azacitidine in Combination With Trametinib May Be Effective for Pediatric Patients With JMML
Researchers have found that the hypomethylating agent azacitidine plus the MEK inhibitor trametinib may be a promising new combination to treat patients with juvenile myelomonocytic leukemia (JMML), according to a preclinical study published by Pasupuleti et al in Molecular Therapy. Background JMML ...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Researchers Identify Potential Biomarkers of Response to Immunotherapy in Patients With Renal Cell Carcinoma
Researchers have revealed that the number of tumor-infiltrating lymphocytes, the state of necrosis, and mutations to the tumor-suppressor gene PBRM1 form a biomarker signature that may predict how patients with renal cell carcinoma will respond to immunotherapy, according to a novel study published ...
USPSTF Announces New Leadership
The U.S. Preventive Services Task Force (USPSTF) recently announced the appointments of Michael J. Barry, MD, as Chair, and Michael Silverstein, MD, MPH, as Vice Chair. Wanda K. Nicholson, MD, MPH, MBA, will remain in her role as Vice Chair. Dr. Barry will assume the role of Chair from Carol M....
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Heavy Toll From Prior Authorization Exceeds Alleged Benefits, According to AMA Survey
The approval process health insurers impose on medical services or drugs is generating a toll that exceeds the purported benefits, according to a physician survey recently released by the American Medical Association (AMA) and shared in a letter to federal health officials.1 Although health...
President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal
On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 million ...
Effect of Smoking Cessation After Diagnosis of Renal Cell Carcinoma on Disease Progression and Survival Outcomes
In a Russian single-institution prospective cohort study reported in the Journal of Clinical Oncology, Sheikh et al found that quitting smoking after a diagnosis of renal cell carcinoma (RCC) was associated with improved disease progression and survival outcomes among patients. Study Details The...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical...
Two Cancer Experts to Head New Tisch Cancer Hospital at Mount Sinai Hospital
Two cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and expected to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been...
Highlights of Novel Therapies Under Study in Genitourinary Cancers
Here are some brief reports from the 2023 ASCO Genitourinary (GU) Cancers Symposium that we hope are of interest. They include real-world evidence about the use of avelumab maintenance in metastatic urothelial carcinoma, data on the feasibility of sequencing radium-223 and Lu-177–PSMA-617 in...
Study Examines Utility, Accuracy of ChatGPT in Offering Breast Cancer Screening Recommendations
A new study suggests that the answers generated by the artificial intelligence (AI) chatbot ChatGPT may provide correct breast cancer screening advice the vast majority of the time; however, the information is sometimes inaccurate or even fictitious, according to the report published by Haver et al ...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Training Oncology Nurses on Primary Palliative Care May Improve End-of-Life Care and Spur Creation of Advance Directives for Patients With Cancer
Specially trained oncology infusion room nurses may be capable of improving advance care planning for patients with advanced cancer at the end of life, according to a new study published by Cohen et al in JNCCN—Journal of the National Comprehensive Cancer Network. Background “Advance care planning...
Addressing Health Disparities in Oncology Care—Legally and Ethically
A health disparity is typically defined as involving a differential in health outcomes between some groups of patients and other groups, for example, between White and Black patients, in which some groups fare better than others. Health inequities are commonly defined as health differences that...
Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities
Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, ...
Primary Overall Survival Analysis of the ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Christopher J. Sweeney, MBBS, and colleagues, the primary overall survival analysis of the phase III ENZAMET trial showed a significant benefit with enzalutamide plus testosterone suppression vs standard nonsteroidal antiandrogen treatment plus testosterone...
Deductibles, Copays May Discourage Patients From Receiving Follow-up Breast Cancer Screenings
Researchers found that 20% of patients attending breast cancer screening appointments were likely to skip additional testing after abnormal findings on their mammograms if there was a deductible or copayment involved, according to a new study published by Ngo et al in Radiology. Background...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv/Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev) in combination with the PD-1 inhibitor pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are...
Pathologic Complete Responses May Be Prognostic of Outcomes for Patients With Soft-Tissue Sarcoma
Researchers have discovered that pathologic complete responses may be associated with improved survival outcomes for patients with localized soft-tissue sarcoma who received preoperative chemoradiotherapy or radiotherapy, according to a novel study published by Wang et al in JAMA Oncology. The new...
More U.S. Patients With Prostate Cancer May Be Electing for Active Surveillance
Since 2010, investigators have discovered that the number of patients with prostate cancer in the United States who are choosing active surveillance over surgery or radiation therapy may be rapidly increasing, according to a new study published by Al Awamlh et al in JAMA Internal Medicine....
Expert Point of View: Mikkael Sekeres, MD, MS
Commenting on these studies of menin inhibitors, Mikkael Sekeres, MD, MS, Professor of Medicine and Chief of the Division of Hematology at the Sylvester Cancer Center, University of Miami Miller School of Medicine, was enthusiastic about the promise of these agents because they are targeted to...
Menin Inhibitors Under Study in KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia
Menin inhibitors are making inroads in the treatment of acute myeloid leukemia (AML). These drugs selectively target KMT2A-rearranged or NPM1-mutant AML, and early studies suggest they will be a welcome addition for patients with these aberrations. KMT2A rearrangements occur in about 5% of patients ...
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD Anderson
The inaugural MD Anderson Clinical Education Symposium on Immunotherapy Toxicity Management (IOTOX) welcomed more than 250 international attendees, both virtually and in person at The University of Texas MD Anderson Cancer Center in Houston on December 3, 2022. The symposium focused on bringing the ...
How Effectively Are You Helping Patients With Cancer at the End of Life?
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
